Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Hemostatic Disorders × Enoxaparin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Venous Thromboembolism 10 Neoplasms 8 Venous Thrombosis 7 Pancreatic Neoplasms 5 Thrombosis 4 Pulmonary Embolism 4 Thromboembolism 3 Hemorrhage 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Ovarian Neoplasms 2 Lymphoma 2 Carcinoma, Non-Small-Cell Lung 2 Venous Thormboembolism 1 Urinary Bladder Neoplasms 1 Thrombocytopenia 1 Stroke 1 Stomach Neoplasms 1 Soft Tissue Neoplasms 1 Multiple Myeloma 1 Malignant Female Reproductive System Neoplasm 1 Lymphoma, Large B-Cell, Diffuse 1 Liver Neoplasms 1 Leukemia 1 Hemostatic Disorders 1 Hematoma 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Gastrointestinal Neoplasms 1 Fibrosis 1

Interventions

dacetuzumab 2 Bortezomib 2 epratuzumab 1 edoxaban 1 Vorinostat 1 Tranexamic Acid 1 Saline Solution 1 Lenalidomide 1 Enoxaparin 1 Dipyrone 1 Dexamethasone 1 Calcium Dobesilate 1 ARQ531 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03570281 2018-06-26

ENCHASE

Samsung Medical Center

Phase 2/3 Unknown

Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡